NHSA to lead first life sciences delegation to Biomed in Israel



NHSA to lead first life sciences delegation to Biomed in Israel

The North’s life sciences landscape will be showcased on an international stage at a leading Israeli medtech conference.

The Northern Health Science Alliance (NHSA), together with the UK BioIndustry Association (BIA) and UK Israel Tech Hub, is leading its first delegation to MIXiii-Biomed in Tel Aviv, which takes place from 14-16 May.

Made up of academics, industry and healthcare professionals, the northern delegation includes representatives from two North West companies - Manchester Science Partnerships and The AMR Centre, based at Alderley Park, Cheshire – alongside NIHR Clinical Research Network, Leeds University, and the Northern Powerhouse at the Department for International Trade.

Attracting over 6,000 healthcare professionals, scientists, engineers, and investors from 45 countries, Biomed will provide an opportunity to showcase the North of England’s excellence in health research and innovation among industry world leaders.

Israel has a thriving life sciences industry, boasting more than 1,400 healthcare start-ups, and it is hoped the NHSA trade mission will provide a platform for northern organisations to tap into this market.

Keith Miller, Head of Corporate Engagement at NHSA, said: “Israel is a life sciences powerhouse and a world leader in key areas of the industry. Since we signed the memorandum of understanding with the UK Israel Tech Hub a year ago, we have continued to strengthen our relationship with leading figures in the country and we’re delighted to be a driving force for the UK presence at this year’s Biomed conference.

“We have the chance to really champion the North’s life sciences offer to a global medtech audience, which we hope will help foster new relationships with exciting companies from around the world to, ultimately, help bring new health and medtech innovations to the North of England.”

Carl Curran, Communications Executive for the AMR Centre, said: “What a fantastic opportunity to explore UK-Israeli partnerships in the antimicrobial space.

“The fight against AMR requires strong, international collaboration, using the expertise and technological achievements of the UK, Israel, and other countries around the globe.

Thomas Renn, Managing Director of Manchester Science Partnerships, said: “We are pleased to be joining the UK's inaugural trade mission to Biomed Israel; it’s absolutely vital amid the uncertainty around the future of international trade with the UK that the life sciences industry reaches out to potential partners, investors and collaborators at key international events such as this. Science, collaboration and partnership is an open endeavour and key to the international R&D science community which we ourselves share with the businesses we work with and help provide opportunities for.

“The landmark investment to create a world-class genomics hub for innovation, precision medicine, translational science and molecular diagnostics in Manchester and the start of construction this year on the £60m expansion of our Citylabs campus, gives us a truly compelling narrative when we are talking to new contacts about plans for both ours and their further growth.”

The delegation will form part of the UK Pavilion in the main exhibition hall at Biomed, alongside other organisations, stakeholders and companies from across the UK.

The four-day visit will also include attendance at an exclusive UK networking event hosted at the British Embassy in Tel Aviv the day before the conference.

Samuel Cronin, Healthcare Innovation Manager at the UK Israel Tech Hub, said: “We are delighted to be working alongside the NHSA to bring a delegation of northern life sciences experts to Biomed. 

“Israel is at the forefront of healthcare innovation and this presents many opportunities for the UK’s healthcare system. We hope that by supporting the North delegation, we can encourage and build lasting links between organisations in the UK and Israel.” 

Jon Kudlick, Interim Director of Business Development and Membership Services at BIA said: “The BIA are delighted to be able to showcase the UK as a global leader in biotech, through the work that we do, and through our members, Sensyne Health and Horizon Discovery.

“Israel is an innovation heavyweight, and MIXiii-Biomed is the perfect forum to showcase the UK’s strengths in advanced therapies, artificial intelligence and more. International engagement is a key priority for the BIA, providing opportunities for our members to grow their profile on a global stage.”

Israel is the world leader in the number of medical device patents per capita, and second in biopharmaceuticals. The country is also leading the way in health information technology, with 100% of Israeli physicians using electronic health records.

Biomed represents an opportunity for participants to experience Israel’s life science-focused tech and innovation first-hand and encourages academic institutions, research facilities and start-ups to connect and collaborate with international health industry leaders.

The conference and exhibition takes place in Tel Aviv from 14-16 May. For more information, visit: http://kenes-exhibitions.com/biomed/